Jazz Pharmaceuticals plc (JAZZ) Stock Price & How to Invest

Jazz Pharmaceuticals is an Ireland-domiciled specialty biopharmaceutical company that develops and markets treatments in neuroscience and oncology. Its largest products are Xywav and Xyrem (low-sodium and legacy oxybates for narcolepsy and idiopathic hypersomnia) and Epidiolex/Epidyolex (a cannabidiol treatment for rare epilepsies), which together anchor a neuroscience portfolio generating several billion dollars a year. Jazz has expanded aggressively into oncology through Zepzelca (small cell lung cancer), Rylaze (pediatric leukemia), Ziihera/zanidatamab (a HER2-directed bispecific antibody) and Modeyso (dordaviprone for diffuse glioma, added via the 2025 Chimerix acquisition).

The investment picture centers on a company that already produces strong non-GAAP profits and free cash flow but trades at a low earnings multiple because investors discount future patent cliffs and generic or branded competition against its biggest drugs. Bulls point to double-digit growth in epilepsy and oncology, new launches, and a valuation that looks inexpensive relative to earnings. Bears focus on reliance on a handful of products, roughly $5 billion of debt, and the constant need for acquisitions and pipeline wins to replace maturing revenue.

The 2026 numbers have mostly supported the bulls on revenue. Second-quarter revenue reached about ~$1.21 billion, up ~15.5% year over year, and management raised full-year revenue guidance to ~$4.60 billion to ~$4.75 billion from the ~$4.25 billion to ~$4.5 billion range set earlier in the year. Earnings were weaker: adjusted EPS of ~$5.71 missed the ~$6.18 consensus, GAAP net income fell to ~$193 million from ~$293 million in the first quarter, and the shares dropped about ~7.6% after the report. Since then Jazz has received a US FDA approval for Ziihera, which headlines described as a first-line HER2-positive gastroesophageal adenocarcinoma (GEA) approval, and Chief Commercial Officer Samantha Pearce has said she intends to retire by June 30, 2027 or on the appointment of a successor. The stock closed at ~$209.58 on October 16, 2026, up ~21% year to date and ~56% over twelve months, but ~21% below its 52-week high of ~$266.38. Third-quarter results are expected around November 4, 2026, with consensus adjusted EPS of only ~$3.07 on ~$1.21 billion of revenue, a sharp step down from recent quarters.

Jazz is concentrated in a few large products, so any acceleration of generic or branded competition against Xywav or Epidiolex could pressure revenue and the stock. The company carries roughly ~$4.4 billion of debt, which raises sensitivity to rates and to integration missteps on acquisitions. Its oncology pivot depends on clinical and regulatory outcomes for assets like Ziihera that are not guaranteed. Oxybates are Schedule III controlled substances sold under restricted REMS programs, adding regulatory and reputational exposure. Execution is a fresh concern after the June quarter, when adjusted EPS of ~$5.71 missed the ~$6.18 consensus even as revenue grew, and consensus for the September quarter sits at only ~$3.07 ahead of the report expected around November 4. The planned retirement of Chief Commercial Officer Samantha Pearce by mid-2027 lands just as the Ziihera launch broadens. Finally, the low valuation multiple reflects the market's skepticism about long-term durability, so sentiment can stay cautious even during good quarters.

22 analysts publish price targets on JAZZ, averaging $294.64 against a $210.23 price as of October 2026, or +40.2%. The published targets run from $225.00 to $337.00, a moderate spread, and the ratings split 20 buy, 2 hold, 0 sell. Over the last six months there have been 10 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full JAZZ forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Jazz Pharmaceuticals plc. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Sleep franchise durability. Xywav, the low-sodium oxybate, remains the cash engine and grew roughly 18% year over year in early 2026. The most optimistic published target, $337.00, assumes this works close to its best case.

The case against. Jazz is concentrated in a few large products, so any acceleration of generic or branded competition against Xywav or Epidiolex could pressure revenue and the stock. The most pessimistic target, $225.00, is roughly what JAZZ is worth if this bites instead.

Read the full bull and bear case on JAZZ, including what would have to change to break either one. Walnut is not an investment adviser.

No. Jazz Pharmaceuticals plc (JAZZ) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Jazz Pharmaceuticals plc's investor relations page or your broker.

• Revenue (TTM): ~$4.6B
• 2026 revenue guidance: ~$4.60B to $4.75B (raised in August)
• Q2 2026 revenue: ~$1.21B (up ~15.5% YoY); adjusted EPS ~$5.71 vs ~$6.18 expected
• Net income (TTM): ~$941M, a ~20% net margin
• P/E: ~14x trailing GAAP, ~8x forward
• Market cap: ~$13.6B at ~$209.58 (October 16, 2026)
• Cash / debt: ~$2.2B / ~$4.4B
• Free cash flow (TTM): ~$1.43B

Jazz combines several billion dollars of high-margin drug revenue, with gross margins above ~90%, with strong non-GAAP earnings, yet trades near ~8 times forward earnings and ~8 times EV to EBITDA. The gap reflects investor concern about patent cliffs and competition rather than current profitability, and the June-quarter earnings miss pulled the shares well off their highs. Net debt of roughly ~$2.2 billion is comfortably covered by free cash flow, so capital allocation and acquisition discipline matter more than solvency. The 22 analysts tracked by Yahoo Finance carry a mean target near ~$295.

If you want JAZZ exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to JAZZ: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get JAZZ exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (DFAS, XMMO), which spreads the position across many companies. Or build it into a focused thematic portfolio, so JAZZ sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where JAZZ fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

JAZZ is a profitable, cash-generative specialty pharma trading at a low multiple (about ~8 times forward earnings in October 2026), where the debate is durability of its lead franchises versus a pivot toward oncology growth that a new Ziihera approval has just pushed forward.

Whether JAZZ is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is JAZZ a buy or a sell?, and where the stock could go from here in the JAZZ stock forecast.

For income investors, whether JAZZ pays a dividend and how the payout looks is covered in does JAZZ pay a dividend? And to weigh JAZZ against a peer, read the full side-by-side comparisons: JAZZ vs ALKS and JAZZ vs IESC.